Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia

The introduction of multiagent treatment protocols has led to a remarkable increase in survival rates for children diagnosed with acute lymphoblastic leukemia, yet for a subpopulation of patients, resistance to chemotherapeutics remains an obstacle to successful treatment. Here we investigate the role of the mitochondrial (or intrinsic) apoptosis pathway in modulating the onset and outcomes of childhood acute lymphoblastic leukemia. Cell death is a highly regulated process that plays an essential role in regulating cell homeostasis, particularly in tissues with high intrinsic proliferating capacity such as the hematopoietic system. Following the underlying paradigm that cis-acting genetic variation can influence disease risk and outcomes by modulating gene expression, we performed a systematic analysis of the proximal promoter regions of 21 genes involved in apoptosis. Using gene reporter assays, we show that promoter variations in 11 intrinsic apoptosis genes, including ADPRT, APAF1, BCL2, BAD, BID, MCL1, BIRC4, BCL2L1, ENDOG, YWHAB, and YWHAQ, influence promoter activity in an allele-specific manner. We also show that correlated promoter variation and increased expression of MCL1 is associated with reduced overall survival among high-risk patients receiving higher doses of corticosteroid, suggesting that increased expression of this anti-apoptosis gene could lead to reduced cell death and influence treatment response in a disease- and dose-responsive manner.

[1]  M. Relling,et al.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Scorilas,et al.  Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia. , 2012, Clinical biochemistry.

[3]  Yuzhen Gao,et al.  A 40-bp insertion/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population. , 2012, Gene.

[4]  D. Neuberg,et al.  ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. , 2011, Blood.

[5]  J. Martinou,et al.  Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. , 2011, Developmental cell.

[6]  D. Sinnett,et al.  ALG: Automated Genotype Calling of Luminex Assays , 2011, PloS one.

[7]  D. Sinnett,et al.  Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia , 2010, Haematologica.

[8]  Michele Purrello,et al.  Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy , 2010, BMC Cancer.

[9]  James Allan,et al.  Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk , 2010, Nature Genetics.

[10]  D. Neuberg,et al.  Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000) , 2009, Leukemia.

[11]  Derek W. Yecies,et al.  MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts , 2009, The Journal of cell biology.

[12]  H. Varmus,et al.  MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family , 2009, Oncogene.

[13]  K. Siminovitch,et al.  Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. , 2008, Blood.

[14]  S. Lowe,et al.  Dissecting eIF4E action in tumorigenesis. , 2007, Genes & development.

[15]  F. Chew,et al.  Multiplexed genotyping of ABC transporter polymorphisms with the Bioplex suspension array , 2007, Biological Procedures Online.

[16]  M. Relling,et al.  Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression. , 2007, Human molecular genetics.

[17]  D. Neuberg,et al.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. , 2007, Blood.

[18]  Daniel Sinnett,et al.  Promoter SNPs in G1/S checkpoint regulators and their impact on the susceptibility to childhood leukemia. , 2007, Blood.

[19]  T. Golub,et al.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.

[20]  Paul Scheet,et al.  Automating sequence-based detection and genotyping of SNPs from diploid samples , 2006, Nature Genetics.

[21]  Cheng Cheng,et al.  The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. , 2006, Blood.

[22]  T. Hudson,et al.  Functional promoter SNPs in cell cycle checkpoint genes. , 2005, Human molecular genetics.

[23]  Michael Knapp,et al.  Maximum‐likelihood estimation of haplotype frequencies in nuclear families , 2004, Genetic epidemiology.

[24]  P. Pahwa,et al.  Prognostic significance of a short sequence insertion in the MCL-1 promoter in chronic lymphocytic leukemia. , 2004, Journal of the National Cancer Institute.

[25]  John D. Storey,et al.  Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach , 2004 .

[26]  M. D. Den Boer,et al.  Resistance to different classes of drugs is associated with impaired apoptosis in childhood acute lymphoblastic leukemia. , 2003, Blood.

[27]  Peter Donnelly,et al.  A comparison of bayesian methods for haplotype reconstruction from population genotype data. , 2003, American journal of human genetics.

[28]  M. Spitz,et al.  Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. , 2003, Lung cancer.

[29]  D. Labuda,et al.  Role of DNA mismatch repair genetic polymorphisms in the risk of childhood acute lymphoblastic leukaemia , 2003, British journal of haematology.

[30]  K. Buetow,et al.  Allelic variation in gene expression is common in the human genome. , 2003, Genome research.

[31]  Alexandra G. Smith,et al.  Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. , 2003, Cancer research.

[32]  M. O’Donovan,et al.  Streamlined approach to functional analysis of promoter-region polymorphisms. , 2002, BioTechniques.

[33]  R. Bataille,et al.  Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. , 2002, Blood.

[34]  M. Minden,et al.  Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. , 2001, Blood.

[35]  Y. Lazebnik,et al.  Evaluation of Apaf-1 and procaspases-2, -3, -7, -8, and -9 as potential prognostic markers in acute leukemia. , 2000, Blood.

[36]  Tak W. Mak,et al.  Two Distinct Pathways Leading to Nuclear Apoptosis , 2000, The Journal of experimental medicine.

[37]  D. Labuda,et al.  Parental smoking, CYP1A1 genetic polymorphisms and childhood leukemia (Québec, Canada) , 2000, Cancer Causes & Control.

[38]  Guido Kroemer,et al.  Mitochondrial control of cell death , 2000, Nature Medicine.

[39]  J C Reed,et al.  Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  GS Salomons,et al.  Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome , 1999, Leukemia.

[41]  J. Friedland,et al.  Pulmonary epithelial cells are a source of IL-8 in the response to Mycobacterium tuberculosis: essential role of IL-1 from infected monocytes in a NF-kappa B-dependent network. , 1999, Journal of immunology.

[42]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[43]  D. Labuda,et al.  Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. , 1999, Blood.

[44]  J R O'Connell,et al.  PedCheck: a program for identification of genotype incompatibilities in linkage analysis. , 1998, American journal of human genetics.

[45]  C. Croce,et al.  Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. , 1998, Blood.

[46]  D. Sinnett,et al.  Frequent deletion of chromosome 12p12.3 in children with acute lymphoblastic leukaemia , 1997, British journal of haematology.

[47]  Xiaodong Wang,et al.  Apaf-1, a Human Protein Homologous to C. elegans CED-4, Participates in Cytochrome c–Dependent Activation of Caspase-3 , 1997, Cell.

[48]  W. Wilmanns,et al.  Association of bcl-2, bax, bcl-xL and interleukin-1 beta-converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia. , 1996, Leukemia.

[49]  Y. Tohno,et al.  Inhibition and down-regulation of poly(ADP-ribose) polymerase results in a marked resistance of HL-60 cells to various apoptosis-inducers. , 1995, Cellular and molecular biology.

[50]  D. Neuberg,et al.  ATF 5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia Running title : Polymorphisms of aspraginase pathway and ALL outcome , 2011 .

[51]  M. Relling,et al.  Expression of SMARCB 1 modulates steroid sensitivity in human lymphoblastoid cells : identification of a promoter snp that alters PARP 1 binding and SMARCB 1 expression , 2007 .

[52]  S. Lowe,et al.  Dissecting eIF 4 E action in tumorigenesis Material Supplemental , 2007 .

[53]  D. Labuda,et al.  Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. , 2004, Blood.

[54]  A. Levine,et al.  A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans , 2004, Cell.

[55]  S H Kaufmann,et al.  Mammalian caspases: structure, activation, substrates, and functions during apoptosis. , 1999, Annual review of biochemistry.

[56]  P. Allen,et al.  Effects of PARP inhibition on drug and Fas-induced apoptosis in leukaemic cells. , 1999, Advances in experimental medicine and biology.

[57]  D. Labuda,et al.  Susceptibility to Childhood Acute Lymphoblastic Leukemia : Influence of CYP 1 A 1 , CYP 2 D 6 , GSTM 1 , and GSTT 1 Genetic Polymorphisms , 1999 .